drugset / Trial / NCT05329545
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Phase 3
Terminated
20 enrolled
Mersana Therapeutics
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
Timeline
- Start
- 2022-06-23
- Primary completion
- 2023-09-29
- Completion
- 2023-09-29
Outcome
Outcome not reported
Stopped: “Study Terminated by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Upifitimab rilsodotin | Other / unclassified | — | Intravenous |